Chinese partners to sell stake in Shanghai Schering-Plough; Elan mulls spin-off of contract manufacturing unit; and much more

> Two Chinese minority owners want to sell their 45 percent stake in the Shanghai Schering-Plough joint venture for some $9.6 million; Schering-Plough will have right of first refusal to those shares. Report

> Irish drugmaker Elan is considering a spin-off of its contract services unit, Elan Drug Technology, executives said at its recent annual general meeting. Report

> At least 30 people have been killed in a series of blasts and a fire that engulfed a pharmaceutical plant in central Iran. Report

> The State of Vermont doesn't like the fact that a new doctor-disclosure bill in the Senate would pre-empt its own, more stringent law requiring drugmakers to divulge payments to physicians. Report

> Morgan Stanley downgraded GlaxoSmithKline to "underweight" on fears that the HPV virus vaccine Cervarix might not be approved in the U.S. by 2009 as expected. Report

> AstraZeneca has sold a portfolio of 16 prescription drugs to biotech group BioPhausia for 535 million Swedish crowns, or about $90 million. Report

> Elderly people with dementia who are given antipsychotics, even for a very short period of time, are more likely to end up in the hospital or even die, new research shows. Report

> Aurobindo Pharma got FDA approval for its version of the blood pressure drug Benazepril HCl. Report

And Finally... A new "drug" called Obecalp is about to hit the children's medication market--only it's not a drug at all. (Hint: read the name backward.) Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.